330 related articles for article (PubMed ID: 28428708)
41. Indoleamine 2, 3-dioxygenase regulation of immune response (Review).
Wu H; Gong J; Liu Y
Mol Med Rep; 2018 Apr; 17(4):4867-4873. PubMed ID: 29393500
[TBL] [Abstract][Full Text] [Related]
42. Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B.
Yoshio S; Sugiyama M; Shoji H; Mano Y; Mita E; Okamoto T; Matsuura Y; Okuno A; Takikawa O; Mizokami M; Kanto T
Hepatology; 2016 Jan; 63(1):83-94. PubMed ID: 26458241
[TBL] [Abstract][Full Text] [Related]
43. Immunological landscape and immunotherapy of hepatocellular carcinoma.
Prieto J; Melero I; Sangro B
Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):681-700. PubMed ID: 26484443
[TBL] [Abstract][Full Text] [Related]
44. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
Ding Z; Dong Z; Chen Z; Hong J; Yan L; Li H; Yao S; Yan Y; Yang Y; Yang C; Li T
Front Immunol; 2021; 12():733530. PubMed ID: 34659220
[TBL] [Abstract][Full Text] [Related]
45. Lack of influence of cyclooxygenese-2 expression in hepatocellular carcinomas on patient survival.
Yildirim Y; Ozyilkan O; Bilezikci B; Akcali Z; Haberal M
Asian Pac J Cancer Prev; 2008; 9(2):295-8. PubMed ID: 18712978
[TBL] [Abstract][Full Text] [Related]
46. Wnt-1 protein as a prognostic biomarker for hepatitis B-related and hepatitis C-related hepatocellular carcinoma after surgery.
Lee HH; Uen YH; Tian YF; Sun CS; Sheu MJ; Kuo HT; Koay LB; Lin CY; Tzeng CC; Cheng CJ; Tang LY; Tsai SL; Wang AH
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1562-9. PubMed ID: 19423534
[TBL] [Abstract][Full Text] [Related]
47. Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier.
Kong J; Diao Z; Deng X; Zhong H; Yao W; Hu X
Oncol Rep; 2007 Jul; 18(1):279-85. PubMed ID: 17549380
[TBL] [Abstract][Full Text] [Related]
48. Upregulation of indoleamine 2,3-dioxygenase in hepatocyte during acute hepatitis caused by hepatitis B virus-specific cytotoxic T lymphocytes in vivo.
Iwamoto N; Ito H; Ando K; Ishikawa T; Hara A; Taguchi A; Saito K; Takemura M; Imawari M; Moriwaki H; Seishima M
Liver Int; 2009 Feb; 29(2):277-83. PubMed ID: 18397228
[TBL] [Abstract][Full Text] [Related]
49. Indoleamine 2,3-Dioxygenase: A Novel Immunotherapeutic Target for Osteosarcoma.
Farooq A; Zulfiqar B; Asghar K
J Cancer Allied Spec; 2023; 9(1):501. PubMed ID: 37197000
[TBL] [Abstract][Full Text] [Related]
50. Neem leaf glycoprotein overcomes indoleamine 2,3 dioxygenase mediated tolerance in dendritic cells by attenuating hyperactive regulatory T cells in cervical cancer stage IIIB patients.
Roy S; Barik S; Banerjee S; Bhuniya A; Pal S; Basu P; Biswas J; Goswami S; Chakraborty T; Bose A; Baral R
Hum Immunol; 2013 Aug; 74(8):1015-23. PubMed ID: 23628394
[TBL] [Abstract][Full Text] [Related]
51. Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis.
Ye LY; Chen W; Bai XL; Xu XY; Zhang Q; Xia XF; Sun X; Li GG; Hu QD; Fu QH; Liang TB
Cancer Res; 2016 Feb; 76(4):818-30. PubMed ID: 26837767
[TBL] [Abstract][Full Text] [Related]
52. Prospects and Challenges for T Cell-Based Therapies of HCC.
Woller N; Engelskircher SA; Wirth T; Wedemeyer H
Cells; 2021 Jun; 10(7):. PubMed ID: 34209393
[TBL] [Abstract][Full Text] [Related]
53. Erianin inhibits indoleamine 2, 3-dioxygenase -induced tumor angiogenesis.
Su C; Zhang P; Liu J; Cao Y
Biomed Pharmacother; 2017 Apr; 88():521-528. PubMed ID: 28129624
[TBL] [Abstract][Full Text] [Related]
54. Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma.
Hong B; Qian Y; Zhang H; Sang YW; Cheng LF; Wang Q; Gao S; Zheng M; Yao HP
World J Gastroenterol; 2016 May; 22(18):4538-46. PubMed ID: 27182163
[TBL] [Abstract][Full Text] [Related]
55. Respiratory syncytial virus induces indoleamine 2,3-dioxygenase activity: a potential novel role in the development of allergic disease.
Ajamian F; Wu Y; Ebeling C; Ilarraza R; Odemuyiwa SO; Moqbel R; Adamko DJ
Clin Exp Allergy; 2015 Mar; 45(3):644-59. PubMed ID: 25627660
[TBL] [Abstract][Full Text] [Related]
56. Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy.
Guo Y; Liu Y; Wu W; Ling D; Zhang Q; Zhao P; Hu X
Biomaterials; 2021 Sep; 276():121018. PubMed ID: 34284200
[TBL] [Abstract][Full Text] [Related]
57. [Current treatment in advanced hepatocellular carcinoma and prospects for immuno-oncology therapy].
Xu JM
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):561-565. PubMed ID: 28835076
[TBL] [Abstract][Full Text] [Related]
58. Autophagy in the "inflammation-carcinogenesis" pathway of liver and HCC immunotherapy.
Yu S; Wang Y; Jing L; Claret FX; Li Q; Tian T; Liang X; Ruan Z; Jiang L; Yao Y; Nan K; Lv Y; Guo H
Cancer Lett; 2017 Dec; 411():82-89. PubMed ID: 28987386
[TBL] [Abstract][Full Text] [Related]
59. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities.
Lu C; Rong D; Zhang B; Zheng W; Wang X; Chen Z; Tang W
Mol Cancer; 2019 Aug; 18(1):130. PubMed ID: 31464625
[TBL] [Abstract][Full Text] [Related]
60. Postoperative therapy options for hepatocellular carcinoma.
Zhong JH; Ma L; Li LQ
Scand J Gastroenterol; 2014 Jun; 49(6):649-61. PubMed ID: 24716523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
